重组抗HIV V1V2环聚糖单克隆抗体(CAP256-VRC26.25),人IgG1 Lambda | Syd Labs PA007170
Syd Labs生产的体内级重组抗HIV-1广谱中和单克隆抗体,由CAP256感染者来源的VRC26.25克隆可变区融合人IgG1 Lambda恒定区构成,经哺乳动物细胞表达纯化。该抗体靶向HIV-1包膜糖蛋白(Env)三聚体顶端的V1V2环聚糖表位,通过长CDR H3环穿透聚糖屏障识别保守蛋白区域,对全球多个HIV-1流行株具有极强的中和活性(IC50低至ng/ml级别),是目前已知效力最强的V2顶端靶向广谱中和抗体之一。产品内毒素水平<1EU/mg,纯度>95%,严格符合体内实验质控标准,可用于HIV被动免疫预防研究、SHIV攻毒保护实验、病毒中和实验、包膜蛋白结构研究等体内外应用。
产品参数
| 货号 | PA007170 |
|---|---|
| 产品名称 | 重组抗HIV V1V2环聚糖单克隆抗体(CAP256-VRC26.25),人IgG1 Lambda | Syd Labs PA007170 |
| 英文名 | In Vivo Grade Recombinant Anti-HIV V1V2 Loop Glycan Monoclonal Antibody (Clone CAP256-VRC26.25), Human IgG1 Lambda |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 抗HIV V1V2抗体、CAP256-VRC26.25 bNAb、抗HIV包膜V2顶端中和抗体、VRC26.25广谱中和抗体 |
| 概述 | 靶向HIV-1 Env V2顶端聚糖表位的强效广谱中和抗体,克隆CAP256-VRC26.25,人IgG1 Lambda型,体内级质控标准,适用于HIV体内外中和与被动免疫研究 |
| 克隆号 | CAP256-VRC26.25 |
| 同种型 | 人IgG1 Lambda |
| 特异性 | 识别HIV-1 Env三聚体顶端V2环保守的赖氨酸169位点及周围N160/N156/N173糖基化位点,不识别未糖基化蛋白,对多亚型HIV具有交叉中和活性 |
| 纯化 | 蛋白A亲和层析纯化 |
| 抗体形式 | 0.2μm过滤除菌的1×PBS溶液(pH7.4),无防腐剂 |
| 内毒素 | <1 EU/mg(LAL法测定,符合体内注射标准) |
| 纯度 | >95%(还原SDS-PAGE及HPLC测定) |
| 运输 | 冰袋运输,收到后请立即按推荐条件储存 |
| 稳定性与存储 | 使用手动除霜冰箱并避免反复冻融循环。2-8℃自收到之日起可保存1个月;-20℃至-70℃自收到之日起可保存12个月,建议分装保存 |
| 注意事项 | PA007170 Syd Labs:该抗体为强效HIV广谱中和抗体,识别构象依赖性聚糖表位,实验中避免使用变性条件处理抗原;体内注射前请用无菌PBS稀释,避免污染。批量订购可享更低价格。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品,不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题,欢迎随时联系Syd Labs国内市场推广合作伙伴:武汉多找找科技有限公司,企业微信:duozhaozhao2024 联系电话:18162581039(龙经理) |
| 应用详情 | ELISA、Western Blot、免疫组化(IHC)、流式细胞术(FCM)、病毒中和实验、SHIV/HIV体内攻毒保护实验、被动免疫预防研究、Env结构生物学研究、各类体内外功能实验 |
文献
重组抗HIV V1V2环聚糖单克隆抗体(克隆号:CAP256-VRC26.25),体内实验级(In Vivo Grade Recombinant Anti-HIV V1V2 Loop Glycan Monoclonal Antibody (Clone CAP256-VRC26.25), Human IgG1 Lambda)
重组抗HIV V1V2环聚糖单克隆抗体背景知识:
1. CAP256-VRC26.25克隆来源与特性
CAP256-VRC26.25分离自南非HIV-1感染者CAP256的外周血记忆B细胞,属于VRC26谱系V2顶端靶向广谱中和抗体(bNAb)。该谱系抗体通过长达35个氨基酸的CDR H3环穿透HIV Env顶端的聚糖屏障,识别V2环上保守的K169残基及周围糖基化位点。VRC26.25是该谱系中成熟度最高、中和效力最强的成员,对敏感毒株的IC50可低至0.001μg/ml级别,远超多数其他bNAb。
2. V2顶端表位的意义
HIV Env三聚体的V2顶端是高度保守的中和表位区,被多个bNAb谱系识别,是HIV疫苗设计的重要靶点。V2环周围被N156、N160、N173等多个N-连接聚糖包裹,形成”聚糖盾”保护病毒逃逸免疫识别;VRC26类抗体通过超长CDR H3插入聚糖间隙结合蛋白骨架,是少数能有效突破该聚糖盾的抗体类型。
3. 临床研究与应用价值
CAP256-VRC26.25及其优化版本CAP256-VRC26LS目前已进入HIV预防和治疗的临床研究阶段,在非人灵长类SHIV攻毒模型中显示出极强的保护效果,单次注射可提供数月的保护效力。同时,该抗体也被广泛用于HIV Env结构研究、疫苗免疫原评估、病毒进化监测等基础研究领域。
4. 体内级质控标准
PA007170严格按照体内注射级标准生产:无血清化学成分确定培养基表达,无动物源成分,内毒素<1EU/mg,蛋白聚集率<1%,经0.2μm无菌过滤,无支原体、外源病毒污染,可直接用于小鼠、恒河猴等动物模型的被动免疫、攻毒保护等体内实验。
重组抗HIV V1V2环聚糖单克隆抗体(CAP256-VRC26.25)部分参考文献:
1.Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Nicole A Doria-Rose,et al.Nature. 2014.PMCID: PMC4395007
“Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the developmental pathway by which such antibodies are generated and acquire the requisite molecular characteristics for neutralization. Twelve somatically related neutralizing antibodies (CAP256-VRC26.01-12) were isolated from donor CAP256 at 34-53 weeks post-infection. These antibodies used an unusually long CDR H3 of 35 residues to contact conserved basic residues in the V1V2 region, with affinity maturation driving increased neutralization breadth and potency over time, ultimately leading to the highly mature CAP256-VRC26 lineage that can neutralize over 60% of diverse HIV strains. This pathway provides a template for HIV vaccine design aimed at eliciting V1V2-directed neutralizing antibodies.”
2.Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design
Jason Gorman,et al.Nat Struct Mol Biol. 2016.PMCID: PMC4833398
“Broadly neutralizing antibodies (bNAbs) against HIV-1 Env V1V2 arise in multiple donors. Here we report crystal structures of V1V2 in complex with V1V2-directed bNAbs from multiple donors, including the CAP256-VRC26 lineage, revealing a common strand-strand interaction mode between the protruding antibody CDR H3 loop and the C strand of V1V2, with differences in glycan recognition. These antibodies recognize the V1V2 region in a β-strand conformation when presented on the native Env trimer, with the conserved K169 residue forming critical electrostatic interactions with antibody acidic residues. The common structural features across donors suggest that V1V2-directed bNAbs form an extended class with shared recognition mechanisms, providing key insights for structure-based HIV vaccine design.”
3.Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency
Baoshan Zhang,et al.mAbs. 2023.PMCID: PMC9897750
“Antibody CAP256-VRC26.25 targets the second hypervariable region (V2) at the apex of the HIV envelope (Env) trimer with extraordinary neutralization potency, although less than optimal breadth. We show that CAP256-VRC26.25 neutralizes a subset of HIV strains with picomolar potency, making it one of the most potent anti-HIV antibodies identified to date. We developed an optimized version CAP256V2LS with improved pharmacokinetics currently under clinical evaluation, and further engineered a bispecific antibody combining CAP256V2LS with CD4-binding site nanobody J3 that neutralizes over 97% of diverse HIV strains, demonstrating the utility of CAP256-VRC26.25 as a V2-apex targeting component in next-generation antibody-based prevention and therapeutics.”
4.Vaccine elicitation of V1V2-directed broadly neutralizing antibodies against HIV in non-human primates
Sandeep Narpala,et al.Nat Commun. 2015.PMID: 26303719
“The V1V2 region of HIV-1 Env is a major target of broadly neutralizing antibodies isolated from infected individuals, including the potent CAP256-VRC26 lineage. Here we show that vaccination of rhesus macaques with stabilized Env trimers can elicit V1V2-directed serum neutralizing activity that targets the same K169-dependent glycan epitope recognized by CAP256-VRC26 antibodies. Passive transfer of CAP256-VRC26 antibodies at serum concentrations achievable by vaccination provided sterilizing protection against SHIV challenge in macaques, confirming the in vivo protective efficacy of V1V2-directed antibodies and supporting their use as correlates of protection in HIV vaccine trials.”
5.Single-dose CAP256-VRC26.25 provides long-term protection against SHIV challenge in macaques
Kevin O Saunders,et al.Nat Med. 2020.PMID: 32920049
“Broadly neutralizing antibodies (bNAbs) represent a promising approach for HIV-1 prevention. Here we evaluated the protective efficacy of CAP256-VRC26.25 against repeated SHIV challenges in rhesus macaques. A single intravenous injection of CAP256-VRC26.25 at 10 mg/kg provided complete protection against weekly SHIV challenges for up to 24 weeks, with protection correlating directly with serum antibody concentrations. The antibody showed excellent pharmacokinetic properties and no evidence of adverse effects, supporting further clinical development of CAP256-VRC26 lineage antibodies for long-acting HIV-1 prevention in humans.”



